论文部分内容阅读
淋巴瘤化疗相关乙型肝炎病毒(HBV)再激活的发生率及病死率均有逐年上升趋势,因此预防化疗所致的HBV再激活尤为重要。发生HBV再激活的危险性与HBV的感染、抗肿瘤药物的应用等有关。对于合并HBV慢性感染的淋巴瘤患者,化疗前应施行预防性抗病毒治疗,从而避免HBV再激活,以完成多疗程化疗,延长生命,提高生活质量。化疗前预防性抗HBV治疗得到普遍认同,本文就这一领域的研究予以综述。
Lymphoma chemotherapy-related hepatitis B virus (HBV) reactivation and mortality have increased year by year, so to prevent chemotherapy-induced HBV reactivation is particularly important. The risk of HBV reactivation and HBV infection, the application of anti-tumor drugs and so on. For patients with chronic lymphocytic infection of lymphoma, chemotherapy should be implemented before the preventive antiviral treatment, thus avoiding the reactivation of HBV to complete the multi-course chemotherapy, prolong life and improve quality of life. Pre-chemotherapy prophylactic anti-HBV treatment is generally accepted, this article reviews the research in this field.